Interleukin-2 in liposomes: Increased intravenous potency and less pulmonary toxicity in the rat
- 1 January 1992
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 27 (1) , 15-31
- https://doi.org/10.1002/ddr.430270103
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Liposomal Encapsulation: Making Old and New Drugs Do New TricksJNCI Journal of the National Cancer Institute, 1989
- Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.The Journal of Experimental Medicine, 1989
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.The Journal of Experimental Medicine, 1989
- Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJournal of Clinical Immunology, 1988
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- Recombinant interleukin-2 directly augments the cytotoxicity of human monocytesNature, 1987
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- A Method of Trace Iodination of Proteins for Immunologic StudiesInternational Archives of Allergy and Immunology, 1966
- New Tables for Multiple Comparisons with a ControlPublished by JSTOR ,1964